Literature DB >> 36056205

Identifying a metabolomics profile associated with masked hypertension in two independent cohorts: Data from the African-PREDICT and SABPA studies.

Michél Strauss-Kruger1,2, Ruan Kruger1,2, Esmé Jansen Van Vuren1,2, Adriaan Jacobs1,2, Roan Louw3, Carina Mels4,5.   

Abstract

Individuals with masked hypertension (MHT) have a greater risk of adverse cardiovascular outcomes than normotensive (NT) individuals. Exploring metabolomic differences between NT and MHT individuals may help provide a better understanding of the etiology of MHT. We analyzed data from 910 young participants (83% NT and 17% MHT) (mean age 24 ± 3 years) from the African-PREDICT and 210 older participants (63% NT and 37% MHT) from the SABPA (mean age 42 ± 9.6 years) studies. Clinic and ambulatory blood pressures (BPs) were used to define BP phenotypes. Urinary amino acids and acylcarnitines were measured using liquid chromatography time-of-flight mass spectrometry in SABPA and liquid chromatography tandem mass spectrometry in the African-PREDICT studies. In the SABPA study, amino acids (leucine/isoleucine, valine, methionine, phenylalanine), free carnitine (C0-carnitine), and acylcarnitines C3 (propionyl)-, C4 (butyryl)-carnitine and total acylcarnitine) were higher in MHT than NT adults. In the African-PREDICT study, C0- and C5-carnitines were higher in MHT individuals. With unadjusted analyses in NT adults from the SABPA study, ambulatory SBP correlated positively with only C3-carnitine. In MHT individuals, positive correlations of ambulatory SBP with leucine/isoleucine, valine, methionine, phenylalanine, C0-carnitine and C3-carnitine were evident (all p < 0.05). In the African-PREDICT study, ambulatory SBP correlated positively with C0-carnitine (r = 0.101; p = 0.006) and C5-carnitine (r = 0.195; p < 0.001) in NT adults and C5-carnitine in MHT individuals (r = 0.169; p = 0.034). We demonstrated differences between the metabolomic profiles of NT and MHT adults, which may reflect different stages in the alteration of branched-chain amino acid metabolism early on and later in life.
© 2022. The Author(s), under exclusive licence to The Japanese Society of Hypertension.

Entities:  

Keywords:  Acylcarnitine; Branched-chain amino acid; Masked Hypertension; Metabolomics

Year:  2022        PMID: 36056205     DOI: 10.1038/s41440-022-01010-2

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   5.528


  41 in total

1.  Incident Left Ventricular Hypertrophy in Masked Hypertension.

Authors:  Cesare Cuspidi; Rita Facchetti; Fosca Quarti-Trevano; Carla Sala; Marijana Tadic; Guido Grassi; Giuseppe Mancia
Journal:  Hypertension       Date:  2019-05-20       Impact factor: 10.190

2.  How to unmask masked hypertension: the role of office aortic blood pressure.

Authors:  Cesare Cuspidi; Marijana Tadic; Guido Grassi
Journal:  Hypertens Res       Date:  2020-11-05       Impact factor: 3.872

3.  A comparative meta-analysis of prospective observational studies on masked hypertension and masked uncontrolled hypertension defined by ambulatory and home blood pressure.

Authors:  Dong-Yan Zhang; Qian-Hui Guo; De-Wei An; Yan Li; Ji-Guang Wang
Journal:  J Hypertens       Date:  2019-09       Impact factor: 4.844

4.  Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome.

Authors:  George S Stergiou; Kei Asayama; Lutgarde Thijs; Anastasios Kollias; Teemu J Niiranen; Atsushi Hozawa; José Boggia; Jouni K Johansson; Takayoshi Ohkubo; Ichiro Tsuji; Antti M Jula; Yutaka Imai; Jan A Staessen
Journal:  Hypertension       Date:  2014-01-13       Impact factor: 10.190

5.  Left ventricular mass independently associates with masked hypertension in young healthy adults: the African-PREDICT study.

Authors:  Nare P Sekoba; Ruan Kruger; Pieter Labuschagne; Aletta E Schutte
Journal:  J Hypertens       Date:  2018-08       Impact factor: 4.844

6.  Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study.

Authors:  Danielle Tientcheu; Colby Ayers; Sandeep R Das; Darren K McGuire; James A de Lemos; Amit Khera; Norman Kaplan; Ronald Victor; Wanpen Vongpatanasin
Journal:  J Am Coll Cardiol       Date:  2015-11-17       Impact factor: 24.094

7.  Masked hypertension and its associated cardiovascular risk in young individuals: the African-PREDICT study.

Authors:  Jane E S Thompson; Wayne Smith; Lisa J Ware; Carina M C Mels; Johannes M van Rooyen; Hugo W Huisman; Leone Malan; Nico T Malan; Leandi Lammertyn; Aletta E Schutte
Journal:  Hypertens Res       Date:  2015-11-26       Impact factor: 3.872

8.  2020 International Society of Hypertension Global Hypertension Practice Guidelines.

Authors:  Thomas Unger; Claudio Borghi; Fadi Charchar; Nadia A Khan; Neil R Poulter; Dorairaj Prabhakaran; Agustin Ramirez; Markus Schlaich; George S Stergiou; Maciej Tomaszewski; Richard D Wainford; Bryan Williams; Aletta E Schutte
Journal:  Hypertension       Date:  2020-05-06       Impact factor: 10.190

Review 9.  Pathophysiology of Hypertension: The Mosaic Theory and Beyond.

Authors:  David G Harrison; Thomas M Coffman; Christopher S Wilcox
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

Review 10.  Masked hypertension and cardiovascular outcomes: an updated systematic review and meta-analysis.

Authors:  Mohan Palla; Hamidreza Saber; Sanjana Konda; Alexandros Briasoulis
Journal:  Integr Blood Press Control       Date:  2018-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.